Gu Xiaobin, Gao Xianshu, Cui Ming, Xie Mu, Ma Mingwei, Qin Shangbin, Li Xiaoying, Qi Xin, Bai Yun, Wang Dian
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, People's Republic of China.
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.
Cancer Manag Res. 2018 May 8;10:1061-1067. doi: 10.2147/CMAR.S157442. eCollection 2018.
This study was aimed to compare survival outcomes in high-risk prostate cancer (PCa) patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP).
The Surveillance, Epidemiology, and End Results (SEER) database was used to identify PCa patients with high-risk features who received RP alone or EBRT alone from 2004 to 2008. Propensity-score matching (PSM) was performed. Kaplan-Meier survival analysis was used to compare cancer-specific survival (CSS) and overall survival (OS). Multivariate Cox regression analysis was used to identify independent prognostic factors.
A total of 24,293 patients were identified, 14,460 patients receiving RP and 9833 patients receiving EBRT. Through PSM, 3828 patients were identified in each group. The mean CSS was 128.6 and 126.7 months for RP and EBRT groups, respectively (<0.001). The subgroup analyses showed that CSS of the RP group was better than that of the EBRT group for patients aged <65 years (<0.001), White race (<0.001), and married status (<0.001). However, there was no significant difference in CSS for patients aged ≥65 years, Black race, other race, and unmarried status. Similar trends were observed for OS. Multivariate analysis showed that EBRT treatment modality, T3-T4 stage, Gleason score 8-10, and prostate-specific antigen >20 ng/mL were significant risk factors for both CSS and OS.
This study suggested that survival outcomes might be better with RP than EBRT in high-risk PCa patients aged <65 years; however, RP and EBRT provided equivalent survival outcomes in older patients, which argues for primary radiotherapy in this older cohort.
本研究旨在比较接受外照射放疗(EBRT)或根治性前列腺切除术(RP)的高危前列腺癌(PCa)患者的生存结局。
利用监测、流行病学和最终结果(SEER)数据库,识别出2004年至2008年间具有高危特征且单独接受RP或EBRT的PCa患者。进行倾向评分匹配(PSM)。采用Kaplan-Meier生存分析比较癌症特异性生存(CSS)和总生存(OS)。多变量Cox回归分析用于识别独立的预后因素。
共识别出24293例患者,14460例接受RP,9833例接受EBRT。通过PSM,每组识别出3828例患者。RP组和EBRT组的平均CSS分别为128.6个月和126.7个月(<0.001)。亚组分析显示,对于年龄<65岁(<0.001)、白种人(<0.001)和已婚状态(<0.001)的患者,RP组的CSS优于EBRT组。然而,对于年龄≥65岁、黑人种族、其他种族和未婚状态的患者,CSS无显著差异。OS也观察到类似趋势。多变量分析显示,EBRT治疗方式、T3-T4期、Gleason评分8-10以及前列腺特异性抗原>20 ng/mL是CSS和OS的显著危险因素。
本研究表明,年龄<65岁的高危PCa患者接受RP的生存结局可能优于EBRT;然而,RP和EBRT在老年患者中提供了等效的生存结局,这支持在该老年队列中进行初始放疗。